{"DataElement":{"publicId":"3447309","version":"1","preferredName":"Uterine Adenosarcoma American Joint Committee on Cancer (AJCC) Edition 7 Pathologic Distant Metastasis M Stage","preferredDefinition":"Extent of the distant metastasis for the uterine adenosarcoma based on evidence obtained from pathologic examination through completion of definitive surgery.","longName":"3444925v1.0:3447094v1.0","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"3444925","version":"1","preferredName":"Uterine Adenosarcoma Pathologic M Stage","preferredDefinition":"The Corpus uteri, or body of uterus, is the part of the uterus above the isthmus, comprising about two thirds of the non-pregnant organ._A low grade malignant neoplasm characterized by the presence of a benign epithelial component (tubular and cleft-like glands) and a low grade sarcomatous component that contains varying amounts of fibrous and smooth muscle tissues. In a minority of cases, the sarcomatous component contains heterologous elements including striated muscle, cartilage, and fat. It occurs in the uterine corpus, ovary, fallopian tube, cervix, and vagina. It may recur and in a minority of cases may metastasize to distant anatomic sites._Caused by or altered by or manifesting disease or pathology._One criteria of the TMN staging system.  M refers to the presence of metastasis.","longName":"3444913v1.0:2207807v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"3444913","version":"1","preferredName":"Corpus Uteri Adenosarcoma","preferredDefinition":"The Corpus uteri, or body of uterus, is the part of the uterus above the isthmus, comprising about two thirds of the non-pregnant organ.:A low grade malignant neoplasm characterized by the presence of a benign epithelial component (tubular and cleft-like glands) and a low grade sarcomatous component that contains varying amounts of fibrous and smooth muscle tissues. In a minority of cases, the sarcomatous component contains heterologous elements including striated muscle, cartilage, and fat. It occurs in the uterine corpus, ovary, fallopian tube, cervix, and vagina. It may recur and in a minority of cases may metastasize to distant anatomic sites.","longName":"C12316:C9474","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Corpus Uteri","conceptCode":"C12316","definition":"The Corpus uteri, or body of uterus, is the part of the uterus above the isthmus, comprising about two thirds of the non-pregnant organ.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Adenosarcoma","conceptCode":"C9474","definition":"A low grade malignant neoplasm characterized by the presence of a benign epithelial component (tubular and cleft-like glands) and a low grade sarcomatous component that contains varying amounts of fibrous and smooth muscle tissues. In a minority of cases, the sarcomatous component contains heterologous elements including striated muscle, cartilage, and fat. It occurs in the uterine corpus, ovary, fallopian tube, cervix, and vagina. It may recur and in a minority of cases may metastasize to distant anatomic sites.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEFC61B5-2B81-B731-E040-BB89AD4344A0","latestVersionIndicator":"Yes","beginDate":"2012-05-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-01","modifiedBy":"ONEDATA","dateModified":"2012-05-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2207807","version":"1","preferredName":"Pathologic M Stage","preferredDefinition":"Pathologic; caused by or altered by or manifesting disease or pathology.:One criteria of the TMN staging system.  M refers to the presence of metastasis.","longName":"C25610:C25727","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pathologic","conceptCode":"C25610","definition":"Caused by or altered by or manifesting disease or pathology.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"M Category","conceptCode":"C25727","definition":"One criteria of the TNM staging system. M refers to the presence of metastasis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-30F5-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEFC61B5-2C43-B731-E040-BB89AD4344A0","latestVersionIndicator":"Yes","beginDate":"2012-05-01","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-01","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"Created for CRF standard harmonization. Released per final community approval. mc 5/7/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3447094","version":"1","preferredName":"Uterine Adenosarcoma American Joint Committee on Cancer (AJCC) Edition 7 Pathologic M Stage","preferredDefinition":"A pathologic finding about one or more characteristics of adenosarcoma, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.  There is no pathologic M0.  (from AJCC 7th Ed.)_A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications._The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.","longName":"3447094v1.0","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"2","maxLength":"2","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"M1","valueDescription":"Adenosarcoma pM1 TNM Finding v7","ValueMeaning":{"publicId":"3447096","version":"1","preferredName":"Adenosarcoma pM1 TNM Finding v7","longName":"3447096","preferredDefinition":"Distant metastasis (excluding adnexa, pelvic and abdominal tissues). (from AJCC 7th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adenosarcoma pM1 TNM Finding v7","conceptCode":"C89627","definition":"Distant metastasis (excluding adnexa, pelvic and abdominal tissues). (from AJCC 7th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF0DF04C-3119-36DC-E040-BB89AD432A18","latestVersionIndicator":"Yes","beginDate":"2012-05-02","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BF0DF04C-3132-36DC-E040-BB89AD432A18","beginDate":"2012-05-02","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-02","modifiedBy":"ONEDATA","dateModified":"2012-05-02","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3447093","version":"1","preferredName":"Adenosarcoma Pathologic Distant Metastasis TNM Finding v7 American Joint Committee on Cancer Stage","preferredDefinition":"A pathologic finding about one or more characteristics of adenosarcoma, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.  There is no pathologic M0.  (from AJCC 7th Ed.):A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications.:The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.","longName":"C89626:C39315:C16899","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adenosarcoma Pathologic Distant Metastasis TNM Finding v7","conceptCode":"C89626","definition":"A pathologic finding about one or more characteristics of adenosarcoma, following the rules of the TNM AJCC v7 classification system as they pertain to distant metastases.  There is no pathologic M0.  (from AJCC 7th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"American Joint Committee on Cancer","conceptCode":"C39315","definition":"A group formed for the purpose of developing a system of clinical staging for cancer that is acceptable to the American medical profession and is compatible with other accepted classifications.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF0DF04C-30ED-36DC-E040-BB89AD432A18","latestVersionIndicator":"Yes","beginDate":"2012-05-02","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-02","modifiedBy":"ONEDATA","dateModified":"2012-05-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF0DF04C-30FE-36DC-E040-BB89AD432A18","latestVersionIndicator":"Yes","beginDate":"2012-05-02","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-02","modifiedBy":"COOPERM","dateModified":"2012-05-07","changeDescription":"Created for CRF standard harmonization. Released per final community approval. mc 5/7/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2192345","version":"1","longName":"Data Standards","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2859963","version":"1","longName":"Standard CRFs","context":"NCIP"},{"publicId":"3434437","version":"1","longName":"Staging/Extent of Disease (by Disease)","context":"NCIP"},{"publicId":"3444895","version":"1","longName":"Corpus Uteri Sarcoma","context":"NCIP"}]},{"publicId":"3461150","version":"1","longName":"Staging","context":"NCIP","ClassificationSchemeItems":[{"publicId":"3461151","version":"1","longName":"AJCC Edition 7","context":"NCIP"}]},{"publicId":"5574838","version":"1","longName":"Staging/Extent of Disease","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"10000596","version":"1","longName":"AJCC Edition 7","context":"NCI Standards"},{"publicId":"5777531","version":"1","longName":"Uterine Adenosarcoma","context":"NCI Standards"}]}],"AlternateNames":[{"name":"LCC","type":"USED_BY","context":"LCC"},{"name":"AECC","type":"USED_BY","context":"AECC"},{"name":"CITN","type":"USED_BY","context":"CITN"},{"name":"PBTC","type":"USED_BY","context":"PBTC"},{"name":"OHSU Knight","type":"USED_BY","context":"OHSU Knight"}],"ReferenceDocuments":[{"name":"Pathologic M Stage","type":"Preferred Question Text","description":"Pathologic M Stage","url":null,"context":"NCI Standards"}],"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Preferred Standard","id":"BF0F910D-4BA5-0D12-E040-BB89AD43049B","latestVersionIndicator":"Yes","beginDate":"2012-05-02","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-05-02","modifiedBy":"HARTLEYG","dateModified":"2021-06-17","changeDescription":"Created for CRF standard harmonization. Released per final community approval. mc 5/7/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}